Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging

J Am Coll Cardiol. 2014 Jan;63(1):86-8. doi: 10.1016/j.jacc.2013.07.050. Epub 2013 Aug 21.

¹ Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: atawakol@partners.org.
² Cardiac MR-PET-CT Program, Division of Cardiac Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
³ Division of Cardiovascular Medicine, University of Cambridge, Cambridge, United Kingdom.
⁴ Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania.
⁵ Metabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, King of Prussia, Pennsylvania; Division of Brain Sciences, Imperial College London, London, United Kingdom.
⁶ Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Peter Munk Cardic Centre and the Heart and Stroke Richard Lewar Centre of Excellence, University of Toronto, Toronto, Ontario, Canada.
⁷ Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

No abstract available

Publication types